ICON Clinical Trials – Overview
ICON Plc. is a global consulting agency that outsources development and commercialization services to various healthcare-related industries, including pharmaceutical companies, biotechnology companies, government and public health organizations, and medical device manufacturers.
The agency is focused on innovating critical factors in the healthcare industry to help reduce costs and improve the quality of products and services.
The agency has a team of experts from across the globe with extensive experience in various therapeutic areas.
Since its inception in 1990, ICON has become one of the world’s most prominent Contract Research Organizations and has received numerous prestigious industry awards for its incredibly high success rate.
Current ICON Clinical Trials
Let’s take a quick look at some of the existing and current clinical trials being conducted by ICON Plc. in 2021:
1 – MY 3853 – 0007
ICON Early Phase Services is organizing a clinical trial for healthy adults between 18 and 45 years old to test the effectiveness of a potential anti-fungal drug.
Participants will need to undergo several tests, including checking medical history, ECGs, vital statistics, drug, alcohol, pregnancy and tobacco testing, along with a physical examination as well as providing urine and blood samples during the trial.
To determine if you are eligible to participate in this clinical trial, you must submit a blood sample for testing after an 8-hour fast. This is a paid trial; participants may be compensated up to US$ 3,000 to cover time and travel expenses.
Please visit the official ICON website for further details on eligibility criteria and the application process.
2 – GL 3507 – 0059
This ICON clinical trial is meant for healthy adult males and females between ages 18 and 55 years and non-smokers.
This clinical trial aims to determine the effectiveness and safety of investigational medicines. This study will focus on an experimental drug developed to treat sickle cell disease and is to be administered orally.
To participate in this study, eligible candidates will be requested to provide their medical history, ECGs, vital signs, drug, alcohol, and tobacco tests, and samples of their blood, urine, and nasopharyngeal fluid.
This is a paid trial. Participants will be compensated with up to US$ 15,480 to cover the cost of time and travel expenses. This trial will also provide partial stipend payments.
To learn more details about eligibility criteria and complete the application process, feel free to call ICON at 210-225-5437 or drop an email at their website using the https://www.appointmentquest.com/scheduler/2110084437.1 registration link.
3 – AM 5480 – 0009
This ICON clinical trial aims to determine the effectiveness and safety of investigational drugs to combat several autoimmune disorders.
The medicine is administered subcutaneously or with an auto-injector or a pre-filled syringe. This study is looking for healthy adult male and female participants aged between 18 and 45.
Potential participants will undergo testing after an 8-hour fast. They are requested to bring any medications they may be currently taking.
This clinical trial does not permit smokers. This is a paid trial and participants will be compensated as much as US$ 10,400 for time and travel expenses.
To find out further details and information on eligibility criteria and the application process, you can choose to visit the website and schedule an appointment using https://www.appointmentquest.com/scheduler/2110084437.1 or you can choose to call ICON directly at 210-225-5437.
4 – RE 3877 – 0008
This ICON clinical trial is aimed at ADPKD patients only. This trial is open for participants who are between 18 and 70 years old and are diagnosed with Autosomal Dominant Polycystic Kidney Disease (ADPKD).
This study aims to discover better and more effective treatment methods for combating the symptoms and effects of ADPKD in patients. This trial includes administrating experimental FDA-approved medicines to determine the best and most effective treatment technique for ADPKD.
For more information on this study, please call the Recruitment Department at ICON directly at 210-225-5437.
5 – NO 0009 – 0537
This ICON clinical trial is meant for breastfeeding female participants aged 18 years and over.
This study aims to decide if an FDA-approved drug that is used to treat type-2 diabetes in adults is present in the breast milk of lactating women and to determine the amount of the drug that can reach the baby through breastfeeding.
This study will help patients and doctors make better decisions for drugs to treat diabetes in women who are breastfeeding. For more information on eligibility criteria and details, please call 210-225-5437 or visit the appointment page at https://www.appointmentquest.com/scheduler/2110084437.1.
These are only the top ICON clinical trials currently being organized by the agency. To find out details on additional clinical trials and trials being planned for the future, feel free to visit the official ICON Plc at https://study-volunteers.iconplc.com/study-finder/.